Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last A$0.12 AUD
Change Today -0.0075 / -6.00%
Volume 105.3M
As of 8:12 PM 05/27/15 All times are local (Market data is delayed by at least 15 minutes).

prima biomed ltd (PRR) Snapshot

Open
A$0.12
Previous Close
A$0.13
Day High
A$0.12
Day Low
A$0.12
52 Week High
05/21/15 - A$0.19
52 Week Low
05/6/15 - A$0.02
Market Cap
196.6M
Average Volume 10 Days
74.3M
EPS TTM
A$-0.01
Shares Outstanding
1.7B
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for PRIMA BIOMED LTD (PRR)

Related News

No related news articles were found.

prima biomed ltd (PRR) Related Businessweek News

No Related Businessweek News Found

prima biomed ltd (PRR) Details

Prima BioMed Ltd. researches, develops, and commercializes medical biotechnology products in Australia. The company develops immunocellular therapeutic products for the treatment of cancer. Its lead product is CVac, an autologous dendritic cell-based product currently in clinical trials for ovarian and pancreatic cancer patients. Prima BioMed Ltd. is based in Sydney, Australia.

31 Employees
Last Reported Date: 08/27/14

prima biomed ltd (PRR) Top Compensated Officers

Chief Executive Officer, Chief Financial Offi...
Total Annual Compensation: A$250.2K
Chief Technical Officer
Total Annual Compensation: A$325.6K
General Counsel and Company Secretary
Total Annual Compensation: A$160.0K
Compensation as of Fiscal Year 2014.

prima biomed ltd (PRR) Key Developments

Prima Biomed Mulls Partner

Prima Biomed Ltd. (ASX:PRR) is seeking partner. The developer of a new ovarian cancer vaccine is seeking a business partner to launch its treatment to patients across the globe following successful clinical trials. "Our concerted focus will now be to find a development partner to make CVac widely available to cancer sufferers around the world," Lucy Turnbull, Chairman of Prima Biomed said.

Prima BioMed Announces Collaboration with NEC Corporation and Yamaguchi University for Immutep's IMP321 in Combination with a Peptide Vaccine

Prima BioMed Ltd. announced a collaboration with NEC Corporation and Yamaguchi University for Immutep's IMP321 in combination with a peptide vaccine developed by NEC and Yamaguchi University. The preclinical study, to be conducted at Yamaguchi University and supported by NEC, will investigate the use of antigen presenting cell activator IMP321 as an adjuvant, together with peptide antigens believed to be involved in hepatocellular cancer.

Prima Biomed Ltd. Reports Consolidated Earnings Results for the Third Quarter Ended March 31, 2015

Prima Biomed Ltd. reported consolidated earnings results for the third quarter ended March 31, 2015. For the period, the company has posted net operating cash flows was AUD 2,405,000 against net operating cash flows used were AUD 4,327,000 a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PRR:AU A$0.12 AUD -0.0075

PRR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for PRR.
View Industry Companies
 

Industry Analysis

PRR

Industry Average

Valuation PRR Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 108.0x
Price/Book 7.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales 121.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PRIMA BIOMED LTD, please visit www.primabiomed.com.au. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.